Updated Enzalutamide Data in Triple-Negative Breast Cancer Presented at the 2015 European Cancer Congress

SAN FRANCISCO, CA--(Marketwired - Sep 26, 2015) - Medivation, Inc. (NASDAQ: MDVN) today announced updated data from a Phase 2 trial evaluating the investigational use of enzalutamide as a single agent for the treatment of advanced triple-negative breast cancer (TNBC). Results from an exploratory overall survival analysis of study data were presented during an oral plenary session at the 2015 European Cancer Congress in Vienna, Austria. The presentation was selected to be featured in the upcoming "Highlights Session" of the 2015 European Cancer Congress.

"We are excited by these updated data as we continue to monitor patients in the trial. Findings from the provisional analysis demonstrate the potential for a diagnostic test to help select women with this particularly aggressive type of breast cancer who may benefit from enzalutamide treatment," said Javier Cortés, M.D., director of the breast cancer program at Vall D'Hebron Institute of Oncology and head of the breast cancer program at Ramon y Cajal University Hospital in Madrid. "This finding is promising and potentially important for patients with TNBC."

A novel gene expression profiling assay was developed using data derived from the Phase 2 trial in patients with advanced TNBC, with a goal of developing a diagnostic test that could select patients who may respond to enzalutamide treatment. Nearly half of the enrolled patients (47%) tested positive for the novel gene expression profiling assay. An exploratory analysis of updated overall survival data demonstrated that those TNBC patients on enzalutamide whose tumors tested positive for the gene expression profile ("diagnostic positive") have to date experienced a 10.5-month longer median survival duration compared to those patients on enzalutamide whose tumor tested negative for the gene expression profile ("diagnostic negative"). The exploratory analysis demonstrated that median overall survival to date for diagnostic positive advanced TNBC patients treated with enzalutamide was 18.0 months (95% CI: 12.0-21.3) compared with 7.5 months for diagnostic negative advanced TNBC patients treated with enzalutamide (95% CI: 4.8 - 11.2).